資源描述：
《西妥昔單抗聯(lián)合放化療治療局部晚期鼻咽癌的臨床療效觀察.pdf》由會員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫。
1、腫瘤藥學(xué)2013年4月第3卷第2期Anti—tumorPharmacy，April2013，Vo1．3，No．2—119蜥西妥昔單抗聯(lián)合放化療治療局部晚期鼻咽癌的臨床療效觀察唐冬寒，張鈺霞，蔡靜(畢節(jié)市人民醫(yī)院，貴州畢節(jié)，551700)摘要：目的探討西妥昔單抗聯(lián)合同期順鉑化療加調(diào)強(qiáng)放療治療局部晚期鼻咽癌的臨床療效及安全性。方法選擇2009年1月至2(J12年1月我院收治的晚期鼻咽癌患者11()例為研究對象，隨機(jī)分為對照組和觀察組，每組55例，對照組患者給予單純調(diào)強(qiáng)適形放射治療，而觀察組患者給予西妥昔單抗聯(lián)合同期順鉑化療加調(diào)強(qiáng)放療．治
2、療4個周期后比較兩組患者的}臨床療效及其不良反應(yīng)的發(fā)生情況．．結(jié)果對照組和觀察組的治療總有效率分別為74．5％和92．7％，觀察組明顯高于對照組(P<()．05)。兩組患音治療過程中均出現(xiàn)不同程度的惡心、嘔吐等消化道反應(yīng)及骨髓抑制，經(jīng)對癥處理后，明顯好轉(zhuǎn)；觀察組患者皮膚痤瘡樣皮疹及口腔黏膜炎的發(fā)生率明顯高于對照組(P<{)．05)。結(jié)論西妥昔單抗聯(lián)合同期順鉑化療加調(diào)強(qiáng)放療治療局部晚期鼻咽癌的近期療效好，但不良反應(yīng)多，臨床需綜合考慮后推廣應(yīng)用。。關(guān)鍵詞：西妥昔單抗；順鉑；調(diào)強(qiáng)放療；鼻咽癌；臨床療效中圖分類號：R73963文獻(xiàn)標(biāo)識碼：A
3、文章編號：2()95—1264(2013)02—0119一(14doi：10．396％j．issn．2(}95-12642013．028TheClinicalEficacyofCetuximabCombinedwithRadiotherapyandChemotherapyintheTreatmentofLocallyAdvancedNasOpharyngealCarcinomaDonghan,ZhangYuxiaCaiJingfThePeoplesHospital0』B記City,B，Gu~hou,551700,China)Abst
4、ract：ObjectiveToinvestigatetheeficacyandsafetyofcetuximabcombinedwithcisplatinchemotherapyandintensity—modulatedradiotherapyinthetreatmentoflocallyadvancednasopharyngealcarcinoma．Methods11()casesoflo-callyadvancednasopharyngealcarcinomahospitalizedfromJanuary2()09toJan
5、uary2012wereselectedandrandomlydividedintothecontrolgroupandobservationgroup(55casesineachgroup)．Thecontrolgroupwastreatedbyintensity—modulatedradiotherapy，whiletheobservationgroupwastreatedbycetuximabcombinedwithcisplatinchemotherapyandintensity——modulatedradiotherapy
6、．Theclinicaleficacyandincidencerateswerecomparedbetweentwogroupsafter4treatmentcy——clesResultsThetotalefectiveratesofcontrolgroupandobservationgroupwererespectively74．5％and927％．whichwassignificantlyhigherintheobservationgroup<()．o5)Gastrointestinalreactionssuchasnausea
7、andvonfittingaswellasmyelosuppressjonwereobservedintwogroups，butwereobviouslyimprovedaftersymptomatictreatment．Theincidenceratesofacne—likerashandora1nmcositisweresignificantlyhigherintheobservationgroupthanthoseofthecontrolgroup<0．()5)ConclusionCetuximabpluscisplatinc
8、hemotherapyandintensity—modulatedradiotherapvhadbetterclinicalef-ficacybutnloreadversereactionsinthetreatmentoflocall
